MONDAY, Nov. 18, 2024 (HealthDay News) -- For children with achondroplasia, oral infigratinib does not result in major safety signals and yields increased annualized height velocity and z score at a ...

BridgeBio (BBIO) announced that 18-month results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with ...

The oral FGFR1-3 selective tyrosine kinase inhibitor infigratinib was found to be safe and effective at the highest studied ...

Investigational therapy infigratinib in children with achondroplasia demonstrated positive phase 2 results in the PROPEL 2 clinical trial, according to an announcement from BridgeBio Pharma. 1 ...

In children with achondroplasia, endochondral bone growth, an essential process by which bone tissue is created, is negatively regulated due to a gain of function mutation in FGFR3. VOXZOGO, a C-type ...

Peer-Reviewed Manuscript Published in Journal of Medicinal Chemistry. In September 2024, a manuscript titled "Discovery of ...

A new targeted therapy aimed specifically at FGFR3, TYRA-300, is showing preliminary promise in patients with advanced FGFR3-altered bladder cancer.Partial responses have been seen in an ongoing phase ...

ABOUT Achondroplasia Achondroplasia is disease in which a genetic mutation of the fibroblast growth factor receptor type 3 (FGFR3) causes FGFR3 to be activated, resulting in an excessive influx of ...

“IND clearance to proceed with BEACH301 is a significant milestone for the achondroplasia community and for TYRA, as we move into the clinic to treat our first rare skeletal dysplasia indication,” ...